Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Patients remitting from chronic migraine (CM) to episodic migraine (EM) and from medication overuse (MO) to no medication overuse (no-MO) across weeks 4, 8 and 12 following fremanezumab treatment
| Week 4 | Week 8 | Week 12 | |
|---|---|---|---|
| CM remission to EM | 22/36 (61.1%) | 26/36 (72.2%) | 27/36 (75%) |
| Sustained remission across weeks 4, 8, 12 | - | 22/22 (100%) | 21/22 (95.5%) |
| MO remission to no-MO | 19/31 (61.2%) | 20/31 (64.5%) | 21/31 (67.7%) |
| Sustained remission across weeks 4, 8, 12 | - | 18/19 (94.7%) | 17/19 (94.4%) |
